Cerebrolysin

What it is

Cerebrolysin is a hydrolysate of purified pig brain proteins: a mixture of low molecular weight peptides and free amino acids, not a defined molecule. It has been manufactured since the 1950s and is registered in a large number of countries for stroke, traumatic brain injury and dementia.

The proposed mechanism is neurotrophic activity, the claim being that the peptide fraction mimics endogenous growth factors such as BDNF and NGF.

What the Cochrane reviews found

This is one of the few compounds on this site where high-quality systematic review evidence exists, and it is worth reading carefully because it points in an uncomfortable direction.

For acute ischaemic stroke, the 2020 Cochrane review pooled seven randomised trials in 1,773 participants. It concluded, at moderate certainty, that cerebrolysin probably has no beneficial effect on death from any cause, and that it probably increases the number of people experiencing non-fatal serious adverse events.

For vascular dementia, the 2019 Cochrane review found possible positive effects on cognitive and global function in mild to moderate cases, but declined to recommend routine use, citing few trials, wide variation in treatment duration, short follow-up and high risk of bias throughout.

Why registration in many countries is not the reassurance it looks like

Cerebrolysin is legally marketed in dozens of jurisdictions. That fact is used heavily in its favour, and it should not carry the weight people give it.

Registration in many countries reflects regulatory history and local approval standards more than it reflects an accumulated evidence base. Several of the trials underpinning those registrations are old, small, and conducted by parties with commercial involvement. The independent synthesis of that same literature, which is what Cochrane does, came back negative on the primary indication.

When broad market presence and independent systematic review disagree, the systematic review is the better guide.

Practical notes

• The adverse event signal is the part to weigh. A neuroprotective agent that probably increases serious adverse events without reducing mortality is a poor trade regardless of how many countries license it.
• The product is not standardisable in the way a peptide is. A brain tissue hydrolysate has batch variation that no certificate of analysis fully resolves.
• Nothing supports use by healthy people for cognitive enhancement. Every trial was in stroke, dementia or brain injury, and the results there were at best equivocal.

Side effects and warning signs

Commonly reported

• Injection-site reactions
• Dizziness and headache
• Sweating and flushing during infusion
• Agitation
• Hypersensitivity reactions

Stop and get medical help

• The Cochrane review of acute ischaemic stroke found a probable increase in non-fatal serious adverse events, which is an unusual finding for a compound marketed as neuroprotective
• Epilepsy or seizure history, since the manufacturer contraindicates it in status epilepticus
• It is a porcine brain-derived product, which carries immunogenicity and contamination considerations distinct from any synthetic peptide

Sources

1. Ziganshina et al., Cerebrolysin for acute ischaemic stroke, Cochrane Database of Systematic Reviews 2020review
2. Cui et al., Cerebrolysin for vascular dementia, Cochrane Database of Systematic Reviews 2019review

From the community

Discussion for this compound concentrates in r/Nootropics.

No threads cached yet.

Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.